INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Grant or awardVerified data

Mohideen Pharis reported DBVT

Chief Medical Officer · DBV Technologies S.A. · Ordinary Shares

Side
A
Value
—
Shares
44.0K
Price
—
Executed
Nov 21, 2025
Disclosed
Nov 25, 2025
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Nov 21 executedNov 25, 2025 disclosed

DBVT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
13/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+9 / 25

No reported dollar value · 43.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · DBVT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    5
    MP
    Mohideen PharisChief Medical Officer
    DBVTDBV Technologies S.A.
    Grant or award
    		A—
    253.0K sh
    		Nov 21, 2025Nov 25, 2025
    traded Nov 21, 2025
    		+4dSEC FORM 4

    Evidence

    31
    MP
    Mohideen PharisChief Medical Officer
    DBVTDBV Technologies S.A.
    Open-market sale
    		SELL$19K
    6,496 sh
    		Nov 20, 2025Nov 25, 2025
    traded Nov 20, 2025
    		+5dSEC FORM 4

    Evidence

    17
    MP
    Mohideen PharisChief Medical Officer
    DBVTDBV Technologies S.A.
    Open-market sale
    		SELL$4,498
    1,624 sh
    		Nov 21, 2025Nov 25, 2025
    traded Nov 21, 2025
    		+4dSEC FORM 4

    Evidence

    9
    TM
    Trapp Kevin MichaelChief Commercial Officer
    DBVTDBV Technologies S.A.
    Grant or award
    		A—
    55.0K sh
    		Nov 21, 2025Nov 24, 2025
    traded Nov 21, 2025
    		+3dSEC FORM 4

    Evidence

    9
    TM
    Trapp Kevin MichaelChief Commercial Officer
    DBVTDBV Technologies S.A.
    Grant or award
    		A—
    316.3K sh
    		Nov 21, 2025Nov 24, 2025
    traded Nov 21, 2025
    		+3dSEC FORM 4

    Evidence

    21
    BV
    Boucinha VirginieChief Financial Officer
    DBVTDBV Technologies S.A.
    Grant or award
    		A—
    32.0K sh
    		Nov 21, 2025Nov 24, 2025
    traded Nov 21, 2025
    		+3dSEC FORM 4

    Evidence

    9
    BV
    Boucinha VirginieChief Financial Officer
    DBVTDBV Technologies S.A.
    Grant or award
    		A—
    192.0K sh
    		Nov 21, 2025Nov 24, 2025
    traded Nov 21, 2025
    		+3dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001760395-25-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 21, 2025
    Published
    Nov 25, 2025
    Ingested by INSIDER
    Nov 5, 04:31 UTC
    Last re-read
    Nov 5, 04:31 UTC

    Extracted facts

    Filer
    Mohideen Pharis
    Role
    Chief Medical Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    DBV Technologies S.A.
    Ticker
    DBVT
    Shares
    44.0K
    Price per share
    $0
    Execution date (reported)
    Nov 21, 2025
    Owned after transaction
    145.5K shares
    Days from execution to publication
    4

    What this establishes

    Mohideen Pharis filed this Form 4 reporting a grant or award of DBVT on Nov 21, 2025. It became public on Nov 25, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Medical Officer
    Mohideen Phariscik:0001760395
    Issuer
    DBV Technologies S.A.cik:0001613780

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.